Magne Børset

 

Mini-CV

• M.D. 1988
• Ph.d. 1996
• Adjunct professor in cell biology and hematological cancer
• Specialist in clinical immunology and transfusion medicine
• Consultant in Dept. of Immunology and Transfusion Medicine, St. Olavs Hospital

 

Research highlights of the multiple myeloma (MM) research group at NTNU, Trondheim

• 1993: Description of a new separation method for MM cells based on antibodies against syndecan-1 (CD138).
• 1994: Establishment of OH-2, an IL-6- and TNF-dependent MM cell line that has since been shown to be a unique hyperdiploid cell line without IgH translocations.
• 1996: The first publication ever on NF-kappa-B activation in human MM cells

·        1996: First publications on expression of hepatocyte growth factor (HGF) and autocrine stimulation of the HGF receptor c-Met in MM cells.

·        1996: Elevation of HGF in serum from patients with MM compared to healthy controls

• 1998: Serum HGF concentration is a prognostic factor for patients with MM and is reduced after response to treatment.
• 1999: Description of a dual role of Fas in myeloma cells; induction of both apoptosis and proliferative responses.
• 1999: HGF induces production of the osteoclast-stimulating cytokine IL-11 in osteoblastic cells.
• 1999: First paper showing proliferation of myeloma cells induced by IL-15 and production of IL-15 mRNA in MM cells.
• 1999: Establishment of a mouse model for MM showing depletion of osteoblasts from affected skeletal tissue.
• 2000: First paper on prognostic impact of serum level of syndecan-1 in patients with MM
• 2000: Polarization of syndecan-1 and heparin-binding molecules on the surface of MM cells
• 2000: High levels of syndecan-1 in MM bone marrow modulate the activity of HGF.
• 2000: First paper on expression of urokinase plasminogen activator (uPA) and the aPA receptor in MM cells.
• 2001: Bone morphogenetic protein-4 (BMP-4) induces apoptosis in MM cells.
• 2001: First paper showing reduced levels of osteoprotegerin (OPG) in serum from patients with MM
• 2002: First paper on proliferative effect of IL-21 on MM cells.
• 2002: Serum IGF-1 is not elevated in MM patients, but is still a prognostic factor
• 2002: OPG is bound and internalized by MM cells.
• 2004: BMP-5, -6 and -7 induce apoptosis in MM cells.
• 2004: Osteopontin is an adhesive factor for MM cells and is increased in serum from patients with MM
• 2005: An inhibitor of HGF receptor c-Met blocks autocrine growth of MM cells.
• 2005: HGF induces adhesion of MM cells to fibronectin
• 2006: First paper showing that toll-like receptors mediate proliferation of MM cells.
• 2007: HGF inhibits BMP-induced osteoclastogensis.
• 2008: Metastasis-associated phosphatase PRL-3 is expressed in malignant but not in healthy plasma cells.
• 2008: HGF promotes migration of MM cells
• 2008: Elevated serum levels of HGF activator in patients with MM